ClinicalTrials.gg
CompletedNCT04182880Updated Apr 13, 2026Results posted

Evaluate the Safety and Pharmacokinetic Profile of CPL-01 in the Management of Acute Postoperative Pain

A Phase 2 interventional study of CPL-01 and Placebo in Abdominoplasty, sponsored by Cali Pharmaceuticals LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Cali Pharmaceuticals LLC · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Evaluate the Safety and Pharmacokinetic Profile of CPL-01 in patients after mini-abdominoplasty

Read the detailed description

This is a randomized, double-blind, study to evaluate the safety, PK profile of CPL-01 for the management of postoperative pain after mini-abdominoplasty surgery.

02

Conditions studied

  • Abdominoplasty
03

In context

Lead sponsor

Cali Pharmaceuticals LLC is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject provides signed, written before participation in the study.
  • Subject is aged ≥18 and ≤70 years at the time of informed consent and is male or female.
  • Subject is scheduled to undergo elective mini-abdominoplasty surgery under general anesthesia without collateral procedures.
  • Female subjects are eligible only if all the following apply:

    1. Not pregnant
    2. Not breastfeeding
    3. Not planning to become pregnant during participation in the study
    4. Committed to the use of an acceptable form of for the duration of the study until at least 30 days after administration of IP.
  • Male subjects must commit to the use of a reliable method of birth control for the duration of the study until at least 30 days after administration of IP or be surgically sterile (biologically or surgically).
  • Subject is free of any physical, mental, or medical conditions which, in the opinion of the investigator, make mini-abdominoplasty or study participation inadvisable.

Exclusion criteria

Exclusion Criteria:

  • Subject has known, suspected, or reported history of alcohol or drug abuse or dependence within the previous 2 years as assessed by the investigator
  • Subject has impaired liver function (e.g., /alanine aminotransferase greater than 3 times the upper limit of the reference range, greater than 1.5 times the upper limit of the reference range unless due to Gilbert's syndrome, active hepatic disease, evidence of liver disease, or other condition such as alcoholism, cirrhosis, or hepatitis, etc.) that suggests the potential for an increased susceptibility to hepatic toxicity with IP exposure.
  • Subject has clinically significant renal abnormalities (creatinine ≥1.5 × ).
  • Subject has ≥7.0%.
  • Subject has participated in another clinical study and/or received an IP (marketed or premarket) within 30 days before surgery.
  • Subject has a history of, or positive test results for, , surface antigen, or virus antibody at Screening.
  • Subject with an upper respiratory infection/cough in the 14 days before surgery.
  • Subjects with a history of significant postoperative nausea and vomiting.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

  • Experimental
    CPL-01

    CPL-01

    Drug: CPL-01

Interventions

  • DrugCPL-01

    CPL-01 will be administered

  • DrugPlacebo

    Placebo will be administered

06

What researchers measure

Primary outcomes

  1. Mean (Peak) Plasma Concentration (Cmax)

    Mean Cmax of 573 ng/mL and occurred at approximately 13 hours. Timepoints tested included before study drug administration and 15, 30, and 45 minutes and 1, 2, 4, 6, 8, 10, 12, 18, 24, 30, 36, 48, 60, 72, 96, and 120 hours after administration.

    Time frame: Baseline through 120 hours after start of study drug administration

07

Results

Posted Sep 21, 2022

Participant flow

Participant flow — Overall Study
MilestonePlaceboCPL-01
Started515
Completed415
Not completed10
Withdrew: Pregnancy10

Outcome measures

PrimaryMean (Peak) Plasma Concentration (Cmax)

Mean Cmax of 573 ng/mL and occurred at approximately 13 hours. Timepoints tested included before study drug administration and 15, 30, and 45 minutes and 1, 2, 4, 6, 8, 10, 12, 18, 24, 30, 36, 48, 60, 72, 96, and 120 hours after administration.

Time frame:
Baseline through 120 hours after start of study drug administration
Reported as:
Mean · ng/mL
Mean (Peak) Plasma Concentration (Cmax)
ng/mLPlaceboCPL-01
Mean (Peak) Plasma Concentration (Cmax)0 ± 0573 ± 258

Adverse events

Collected over 28 Days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo4/5 (80%)0/5 (0%)4/5 (80%)
CPL-0111/15 (73.3%)0/15 (0%)11/15 (73.3%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlaceboCPL-01
HypoaesthesiaNervous system disorders2/51/15
Back PainMusculoskeletal and connective tissue disorders2/50/15
ConstipationGastrointestinal disorders1/54/15
NauseaGastrointestinal disorders1/53/15
VomitingGastrointestinal disorders1/50/15
Feeling HotGeneral disorders1/51/15
DizzinessNervous system disorders1/51/15
DysgeusiaNervous system disorders1/51/15
SyncopeNervous system disorders1/50/15
MalaiseGeneral disorders1/50/15

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboCPL-01Total
<=18 years000
Between 18 and 65 years51520
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboCPL-01Total
Female51520
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboCPL-01Total
Hispanic or Latino000
Not Hispanic or Latino51520
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboCPL-01Total
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American41317
White022
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Chesapeake Research Group
    Pasadena, Maryland 21122, United States
09

References and documents

Publications

  • Pope S, Crean C, Thrasher S, Xu H, Chen PJ, Chen L, Hu D, Onel E. Comparison of Pharmacokinetics of Long-Acting Local Analgesics: CPL-01, a Novel Extended-Release Ropivacaine, Demonstrates Consistent and Predictable Exposure Compared with Liposomal Bupivacaine. Clin Drug Investig. 2025 Feb;45(2):51-58. doi: 10.1007/s40261-025-01419-w. Epub 2025 Jan 29. PubMed 39881115 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Feb 2020, 1 month.

Results were first posted in Sep 2022, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2019
First posted
Dec 2, 2019
StartActual
Jan 6, 2020
Primary completionActual
Feb 28, 2020
CompletionActual
Feb 28, 2020
Results first posted
Sep 21, 2022
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04182880
Lead sponsor
Cali Pharmaceuticals LLC
Responsible party
Sponsor
First posted
Dec 2, 2019
Start date
Jan 6, 2020
Primary completion
Feb 28, 2020
Completion
Feb 28, 2020
Results posted
Sep 21, 2022
Last update
Apr 13, 2026

Study contacts

Erol Onel, MD
study chair · Cali Biosciences

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CPL-01

Start the discussion